Previous 10 |
CAMBRIDGE, Mass., June 18, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced that it completed the process to v...
CAMBRIDGE, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of Salar R...
Anchiano Therapeutics (NASDAQ: ANCN ): Q1 net loss of $18.45M More news on: Anchiano Therapeutics Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
– Closed $30.5 million U.S. Initial Public Offering in February 2019 – CAMBRIDGE, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and d...
News, Short Squeeze, Breakout and More Instantly...
Anchiano s hareholders approve all resolutions at shareholder meeting The merged company is expected to receive approximate gross proceeds from the private financing of $ 45 .5 million, which will be used to a dvance the Chemomab...
Are These 5 Biotech Penny Stocks Worth Watching? With the extraordinary times we live in, Covid has resulted in a large investor focus on biotech penny stocks. Within the stock market, there’s no shortage of interesting biotech companies to choose from. In 2021, it’s best ...
NEW YORK, NY / ACCESSWIRE / February 3, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in N...